<DOC>
	<DOCNO>NCT00003360</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell deliver tumor-killing substance , radioactive iodine , without harm normal cell . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody treat patient advanced colorectal cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Define toxicity determine maximum tolerate dose iodine I 131 humanize monoclonal antibody A33 ( 131I-huAb A33 ) patient advanced colorectal cancer . II . Describe pharmacokinetics biodistribution 131I-huAb A33 external imaging patient . III . Determine effect human antihuman antibody response pharmacokinetics target 131I-huAb A33 patient population . IV . Determine whether dose plan methodology use adequately safely applied routine radioimmunotherapy planning . OUTLINE : Patients receive iodine I 131 humanize monoclonal antibody A33 ( 131I-huAb A33 ) IV infusion 20 minute every 6-8 day 8 week ( depend dosage ) . Patients receive minimum 6 week treatment . In absence disease progression unacceptable toxicity , patient retreat sooner 6 week previous course . Cohorts 3-6 patient receive escalate dos 131I-huAb A33 determine maximum tolerate dose ( MTD ) . The MTD define high dose 2 6 patient experience dose limit toxicity . Patients follow 6 week last treatment . PROJECTED ACCRUAL : There 3-24 patient accrue study 16 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced colorectal cancer Must unresectable ( Stage IV ) disease fail refused conventional chemotherapy Measurable disease conventional imaging method Liver involvement great 50 % No CNS involvement Not positive human antimouse antibody titer PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80100 % Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm3 Platelet count least 150,000/mm3 Prothrombin time le 1.3 time control Hepatic : Bilirubin great 1 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No significant cardiac disease ( New York Heart Association class II/IV heart disease ) Other : No serious infection require treatment antibiotic No serious illness Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No prior mouse monoclonal antibody antibody fragment , chimeric humanize antibody , construct derive antibody At least 4 week since prior immunotherapy Chemotherapy : No prior mitomycin/radiotherapy combination At least 4 week since prior chemotherapy Endocrine therapy : No concurrent steroids antiinflammatory agent Radiotherapy : No prior radiotherapy/mitomycin combination Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>